Legend Biotech launches grant program for myeloma research

Legend Biotech Corporation, a U.S.-based biotech company, has announced the launch of its Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program. This annual grant initiative is aimed at early-career healthcare professionals working on cell therapy approaches for multiple myeloma treatment. Applications for the program are open until November 20, 2026, and will be awarded in two categories: the Emerging Educator Excellence in CAR-T Award and the Emerging Innovator Innovation in CAR-T Award.

The grant review process will be overseen by an independent steering committee of experts in cellular therapy and hematologic malignancies. Recipients will be notified in December 2026 and invited to a recognition event in 2027. Legend Biotech is known for developing and marketing CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma in collaboration with Johnson & Johnson.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.